ICER aims to define HTA approach to gene therapies

The Institute for Clinical and Economic Review is taking the lead in defining the global health technology assessment (HTA) process for potentially curative treatments such as gene therapies, strengthening its position as the de facto HTA in the U.S.

In a new collaboration with National Institute for Health and Care Excellence

Read the full 505 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE